• Programs that address identified needs in ANCA vasculitis (AAV), IgA nephropathy (IgAN) and Iron Deficiency such as awareness of disease burden including healthcare utilization, accelerate diagnosis, improve education and management to improve patient care.

• Programs that improve awareness and education on the management emergent bleeding and acute hemorrhage scenarios and health economic aspects of blood management and concentrate administration.
• Programs that advance principles of Patient Blood Management (PBM).

• Programs that educate on the importance of timely diagnosis and adequate treatment (appropropriate prophylaxis) and their correlation with clinical, quality of life, joint health and socioeconomic outcomes in bleeding disorders, specifically hemophilia and von Willibrand disease.
• Programs designed to educate providers and enable patient real-world experience sharing with hemophilia B gene therapy.

• Programs pertaining to improvements in diagnosis of HAE.
• Role of shared decision making between HCP and patient in determining their appropriate HAE management plan.
• Programs that enhance clinician’s and patient’s knowledge of hereditary angioedema types 1, 2 and HAE with normal C1 inhibitor.
• Programs that raise awareness around the HAE patient and caregiver journey/experience, real-world evidence, and quality of life aspects of their disease.
• Programs pertaining to identification of unmet needs and burden of HAE, including its psychosocial impact for patients and caregivers
• Programs to empower patients to aim to achieve complete disease control (both attack free and normalization of life)

• Programs that enhance awareness of CIDP and its unmet needs, improve timelines and accuracy of diagnosis, or improve standards of neuromuscular disease management.
• Programs that foster knowledge of appropriate management and assessment of patient outcomes in CIDP including patient preferences for management.
• Programs that expand the knowledge of CIDP at home disease management.

• Programs that raise awareness of PID disease burden and improve accuracy and shorten time to diagnosis.
• Programs that expand the knowledge of therapeutic strategies and their value in management of antibody deficiencies and improving quality of including at home treatment.

• Programs that raise awareness of SID disease burden and improve accuracy and shorten time to diagnosis.
• Programs that foster collaboration between immunodeficiency and haem-oncology community to enable greater awareness, timely diagnosis, appropriate management and improved patient outcomes.
• Programs that expand the knowledge of therapeutic strategies and their value in management of antibody deficiencies and improving quality of including at home treatment.

A: You will receive a Grant submission confirmation via email which will include your Request ID. Please keep this for your records. This email will also provide a link to the Grant application to continue to follow up on the request.

A: You will receive an email notification of the status of the Grant after the Committee completes the review.